SMAD4 Antibody

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2) . These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. SMAD4 is absent in approximately 80% of pancreatic adenocarcinoma, but rarely in endometrial, colorectal, ovarian, lung, breast adenocarcinomas, and malignant melanom. SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients.

9007-83-4

Immunohistochemistry (FFPE) : 1-2 µg/mL for 30 minutes at RT

Q13485

Human

Recombinant full-length human protein was used as the immunogen for the SMAD4 antibody.

SMAD4/2440

IHC-P

Protein G affinity chromatography

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

Store the SMAD4 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

This SMAD4 antibody is available for research use only.

Store the SMAD4 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide) .

0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05% sodium azide

Optimal dilution of the SMAD4 antibody should be determined by the researcher.

Cytoplasmic & Nuclear